A303360 Stock Overview

Designs, develops, and sells diagnostic kits in South Korea. More details

A303360 fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	0/6
Past Performance	0/6
Financial Health	0/6
Dividends	0/6

Risk Analysis

Has not reported any financial data

Does not have a meaningful market cap (₩36B)

My Notes

Capture your thoughts, links and company narrative

Protia Inc. Competitors

PCL

KOSDAQ:A241820

₩36.2b

MEKICS

KOSDAQ:A058110

₩31.9b

CU Medical Systems

KOSDAQ:A115480

₩41.5b

Wonbiogen

KOSDAQ:A307280

₩42.1b

Price History & Performance

Summary of share price highs, lows and changes for Protia
Historical stock prices
Current Share Price	₩2,730.00
52 Week High	₩3,590.00
52 Week Low	₩2,430.00
Beta	0
1 Month Change	3.61%
3 Month Change	-9.00%
1 Year Change	-13.61%
3 Year Change	-54.42%
5 Year Change	-61.00%
Change since IPO	-69.67%

Recent updates

Shareholder Returns

	A303360	KR Medical Equipment	KR Market
7D	1.1%	0.7%	-1.6%
1Y	-13.6%	-2.0%	-9.1%

Return vs Industry: A303360 underperformed the KR Medical Equipment industry which returned -2% over the past year.

Return vs Market: A303360 underperformed the KR Market which returned -9.1% over the past year.

Price Volatility

Is A303360's price volatile compared to industry and market?
A303360 volatility
A303360 Average Weekly Movement	5.4%
Medical Equipment Industry Average Movement	7.3%
Market Average Movement	6.6%
10% most volatile stocks in KR Market	12.6%
10% least volatile stocks in KR Market	3.3%

Stable Share Price: A303360 has not had significant price volatility in the past 3 months compared to the KR market.

Volatility Over Time: A303360's weekly volatility (5%) has been stable over the past year.

About the Company

Founded	Employees	CEO	Website
2000	n/a	Kook Jin Lim	www.protia.co.kr

Protia Inc. designs, develops, and sells diagnostic kits in South Korea. The company offers PROTIA Allergy-Q, an assay kit for quantitative determination of specific IgE antibodies against individual allergens in human serum using immunoblotting technique; ImmuneCheck IgG, a whole blood test kit for total IgG concentration measurement; and TriCheck-C, an in vitro diagnostic kit for the qualitative test of human chorionic gonadotropin in human urine samples for the pregnancy diagnosis. It also provides protia food iga, a chronic food intolerance test to identify the foods that do not fit, and stay healthy; anitia canine ige, a serum to identify the cause of the allergy; anicheck bovine igg, a colostrum for feeding calves.

Protia Inc. Fundamentals Summary

How do Protia's earnings and revenue compare to its market cap?
A303360 fundamental statistics
Market cap	₩35.93b
Earnings (TTM)	₩0
Revenue (TTM)	n/a

n/a

P/E Ratio

n/a

P/S Ratio

Is A303360 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
A303360 income statement (TTM)
Revenue	₩0
Cost of Revenue	₩0
Gross Profit	₩0
Other Expenses	₩0
Earnings	₩0

Last Reported Earnings

n/a

Next Earnings Date

n/a

Earnings per share (EPS)	0
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	0.0%

How did A303360 perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2024/12/20 10:49
End of Day Share Price	2024/12/20 00:00
Earnings	N/A
Annual Earnings	N/A

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Protia Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution